FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo®

     FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo®

- Toujeo dossier already accepted by EMA -

PR Newswire

PARIS, July 8, 2014

PARIS, July 8, 2014 /PRNewswire/ --Sanofi (EURONEXT: SAN and NYSE: SNY)
announced today thatthe U.S. Food and Drug Administration (FDA) has accepted
for review the company's New Drug Application (NDA) for Toujeo® (insulin
glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin.
The acceptance of the NDA follows the acceptance of the marketing
authorization dossier for Toujeo by the European Medicines Agency (EMA) for EU
countries on May 27, 2014.

"By reaching this key milestone in the approval process, we are pleased to
take another step forward with Toujeo, an investigational new basal insulin
that has been evaluated in a broad range of people living with diabetes," said
Pierre Chancel, Senior Vice President, Global Diabetes at Sanofi. "With the
FDA's acceptance of our submission, we are anticipating the regulatory
decision for marketing authorization for Toujeo in the U.S. in the first half
of 2015."

The NDA for Toujeo is based on results from the EDITION clinical trial
program, which is a worldwide and extensive series of Phase III studies
evaluating the efficacy and safety of Toujeo in over 3,500 people from broad
and diverse diabetes populations.

Toujeo is the trade name for insulin glargine [rDNA origin] injection, 300
U/mL; formerly abbreviated as "U300". U300 is not currently approved or
licensed anywhere in the world.

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths in
the field of healthcare with seven growth platforms: diabetes solutions, human
vaccines, innovative drugs, consumer healthcare, emerging markets, animal
health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in
New York (NYSE: SNY).

Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2013. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.


Contact: Media Relations, Jack Cox, Tel.: + (33) 1 53 77 94 74,
jack.cox@sanofi.com, or Investor Relations, Sébastien Martel, Tel.: + (33) 1
53 77 45 45, ir@sanofi.com, or Global Diabetes Communications, Tilmann
Kiessling, Mobile: +(49) 17 26 15 92 91, Tilmann.kiessling@sanofi.com, or U.S.
Diabetes Communications, Susan Brooks, Office: +1 (0) 908 981 6566, Mobile: +1
(0) 201 572 49 94, susan.brooks@sanofi.com
Press spacebar to pause and continue. Press esc to stop.